|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
Globocan estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li K and Lin T: Chinese Bladder Cancer
Consortium. Xue W, Mu X, Xu E, Yang X, Chen F, Li G, Ma L, et al:
Current status of diagnosis and treatment of bladder cancer in
China-analyses of Chinese bladder cancer consortium database. Asian
J Urol. 2:63–69. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lobo N, Afferi L, Moschini M, Mostafid H,
Porten S, Psutka SP, Gupta S, Smith AB, Williams SB and Lotan Y:
Epidemiology, screening, and prevention of bladder cancer. Eur Urol
Oncol. 5:628–639. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen H, Yang W, Xue X, Li Y, Jin Z and Ji
Z: Integrated analysis revealed an inflammatory cancer-associated
fibroblast-based subtypes with promising implications in predicting
the prognosis and immunotherapeutic response of bladder cancer
patients. Int J Mol Sci. 23(15970)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Babjuk M, Burger M, Capoun O, Cohen D,
Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F,
Masson-Lecomte A, Mostafid AH, et al: European association of
urology guidelines on non-muscle-invasive bladder cancer (Ta, T1,
and carcinoma in situ). Eur Urol. 81:75–94. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stein JP and Skinner DG: Radical
cystectomy for invasive bladder cancer: Long-term results of a
standard procedure. World J Urol. 24:296–304. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Witjes JA, Bruins HM, Cathomas R, Compérat
EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A,
Neuzillet Y, et al: European association of urology guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2020
guidelines. Eur Urol. 79:82–104. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dale M and Nicklin MJ: Interleukin-1
receptor cluster: Gene organization of IL1R2, IL1R1, IL1RL2
(IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human
chromosome 2q. Genomics. 57:177–179. 1999.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ngo VL, Kuczma M, Maxim E and Denning TL:
Il-36 cytokines and gut immunity. Immunology. 163:145–154.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tomuschat C, O'Donnell AM, Coyle D and
Puri P: Altered expression of IL36γ and IL36 receptor (IL1RL2) in
the colon of patients with Hirschsprung's disease. Pediatr Surg
Int. 33:181–186. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Scheibe K, Kersten C, Schmied A, Vieth M,
Primbs T, Carlé B, Knieling F, Claussen J, Klimowicz AC, Zheng J,
et al: Inhibiting interleukin 36 receptor signaling reduces
fibrosis in mice with chronic intestinal inflammation.
Gastroenterology. 156:1082–1097.e11. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Baker KJ, Brint E and Houston A:
Transcriptomic and functional analyses reveal a tumour-promoting
role for the IL-36 receptor in colon cancer and crosstalk between
IL-36 signalling and the IL-17/IL-23 axis. Br J Cancer.
128:735–747. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Poudel M, Bhattarai PY, Shrestha P and
Choi HS: Regulation of interleukin-36γ/IL-36R signaling axis by
PIN1 in epithelial cell transformation and breast tumorigenesis.
Cancers (Basel). 14(3654)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang P, Yang W, Guo H, Dong HP, Guo YY,
Gan H, Wang Z, Cheng Y, Deng Y, Xie S, et al: IL-36γ and IL-36Ra
reciprocally regulate NSCLC progression by modulating GSH
homeostasis and oxidative stress-induced cell death. Adv Sci
(Weinh). 8(e2101501)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kovach MA, Che K, Brundin B, Andersson A,
Asgeirsdottir H, Padra M, Lindén SK, Qvarfordt I, Newstead MW,
Standiford TJ and Lindén A: IL-36 cytokines promote inflammation in
the lungs of long-term smokers. Am J Respir Cell Mol Biol.
64:173–182. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Guo Q, Zhao L, Yan N, Li Y, Guo C, Dang S,
Shen X, Han J and Luo Y: Integrated pan-cancer analysis and
experimental verification of the roles of tropomyosin 4 in gastric
cancer. Front Immunol. 14(1148056)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dyrskjøt L, Hansel DE, Efstathiou JA,
Knowles MA, Galsky MD, Teoh J and Theodorescu D: Bladder cancer.
Nat Rev Dis Primers. 9(58)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lokeshwar VB and Soloway MS: Current
bladder tumor tests: Does their projected utility fulfill clinical
necessity? J Urol. 165:1067–1077. 2001.PubMed/NCBI
|
|
23
|
Grossman HB, Messing E, Soloway M, Tomera
K, Katz G, Berger Y and Shen Y: Detection of bladder cancer using a
point-of-care proteomic assay. JAMA. 293:810–816. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wen S, He L, Zhong Z, Mi H and Liu F:
Prognostic model of colorectal cancer constructed by eight
immune-related genes. Front Mol Biosci. 7(604252)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen YC, Gonzalez ME, Burman B, Zhao X,
Anwar T, Tran M, Medhora N, Hiziroglu AB, Lee W, Cheng YH, et al:
Mesenchymal stem/stromal cell engulfment reveals metastatic
advantage in breast cancer. Cell Rep. 27:3916–3926.e5.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hao M, Li H, Yi M, Zhu Y, Wang K, Liu Y,
Liang X and Ding L: Development of an immune-related gene
prognostic risk model and identification of an immune infiltration
signature in the tumor microenvironment of colon cancer. BMC
Gastroenterol. 23(58)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Baker KJ, Buskiewicz E, Finucane M,
Chelliah A, Burke L, Houston A and Brint E: IL-36 expression is
increased in NSCLC with IL-36 stimulation of lung cancer cells
promoting a pro-tumorigenic phenotype. Cytokine.
165(156170)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Drosten M and Barbacid M: Targeting the
MAPK pathway in KRAS-driven tumors. Cancer Cell. 37:543–550.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ullah R, Yin Q, Snell AH and Wan L:
RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer
Biol. 85:123–154. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lee S, Rauch J and Kolch W: Targeting MAPK
signaling in cancer: Mechanisms of drug resistance and sensitivity.
Int J Mol Sci. 21(1102)2020.PubMed/NCBI View Article : Google Scholar
|
